Sarepta Therapeutics (NASDAQ:SRPT) Now Covered by HC Wainwright

HC Wainwright assumed coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a report released on Monday, MarketBeat Ratings reports. The brokerage issued a sell rating and a $80.00 price target on the biotechnology company’s stock. HC Wainwright also issued estimates for Sarepta Therapeutics’ Q4 2024 earnings at $1.53 EPS, FY2024 earnings at $2.30 EPS, Q1 2025 earnings at $2.32 EPS, Q2 2025 earnings at $2.69 EPS, Q3 2025 earnings at $2.75 EPS, Q4 2025 earnings at $2.82 EPS and FY2025 earnings at $10.58 EPS.

A number of other research firms have also recently commented on SRPT. Cantor Fitzgerald upgraded Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and increased their price target for the company from $152.00 to $167.00 in a research note on Thursday, November 7th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $182.00 price objective on shares of Sarepta Therapeutics in a research report on Monday, October 21st. Guggenheim boosted their target price on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Evercore ISI decreased their price target on shares of Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating for the company in a report on Thursday, November 7th. Finally, StockNews.com lowered shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, November 20th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, twenty have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $175.77.

Sarepta Therapeutics Price Performance

Shares of SRPT opened at $137.94 on Monday. The company has a 50 day moving average of $122.16 and a two-hundred day moving average of $131.43. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics has a twelve month low of $78.67 and a twelve month high of $173.25. The company has a market cap of $13.18 billion, a price-to-earnings ratio of 110.35 and a beta of 0.81.

Institutional Investors Weigh In On Sarepta Therapeutics

Several large investors have recently bought and sold shares of the company. Farallon Capital Management LLC lifted its position in shares of Sarepta Therapeutics by 102.8% in the first quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company’s stock valued at $317,630,000 after acquiring an additional 1,243,427 shares in the last quarter. Wellington Management Group LLP lifted its holdings in Sarepta Therapeutics by 32.3% in the 3rd quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company’s stock valued at $340,527,000 after purchasing an additional 665,087 shares in the last quarter. Erste Asset Management GmbH acquired a new stake in Sarepta Therapeutics during the 3rd quarter worth $79,425,000. Janus Henderson Group PLC boosted its stake in Sarepta Therapeutics by 14.2% during the 3rd quarter. Janus Henderson Group PLC now owns 4,358,511 shares of the biotechnology company’s stock worth $544,408,000 after purchasing an additional 543,143 shares during the last quarter. Finally, Principal Financial Group Inc. grew its holdings in shares of Sarepta Therapeutics by 693.7% during the second quarter. Principal Financial Group Inc. now owns 363,011 shares of the biotechnology company’s stock worth $57,356,000 after buying an additional 317,277 shares in the last quarter. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.